announced today a collaboration agreement with Eisai Inc. on development and analysis of novel therapeutics for the treating psychiatric disorders. The multi-calendar year collaboration will entail pre-scientific validation of potential therapeutics resulting in clinical proof-of-concept studies. Now together with Eisai, Aestus will test these products to identify the very best candidates for potential subsequent advancement in clinical trials. Related StoriesLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E.Major programs of IDSA consist of publication of two journals, The Journal of Infectious Scientific and Diseases Infectious Diseases, an Annual Meeting, awards and fellowships, public policy and advocacy, clinical affairs and other membership services. The Society, which includes 7,000 people, was founded in 1963 and is headquartered in Alexandria, Va.. Allen Institute for Human brain Technology receives $8.7 million NIH grant to explore synapses The Allen Institute for Brain Science, in a project led by Stephen Smith, Ph.D., Senior Investigator, offers been awarded an $8.7 million, five-year Transformative Research Award from the National Institutes of Health to lead the creation of a publicly accessible style of synapse populations in mouse and individual brains.